# Recursion Pharmaceuticals, Inc. (RXRX) stock news and updates

As of November 18, 2026. Source: https://www.clearthesis.ai/updates/RXRX

## Our view on the Recursion Pharmaceuticals, Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/RXRX

## Latest updates on Recursion Pharmaceuticals, Inc.

### FDA agrees on Phase 3 trial design for Recursion's lead drug

*November 18, 2026 · news · significance: major · signal: positive*

The company reached an agreement with the FDA, the agency that approves new medicines, on how to design the final Phase 3 trial for its lead drug candidate. This drug, REC-4881, aims to treat a rare genetic condition that causes thousands of polyps to grow in the colon. There are currently no approved drug treatments for this disease. This is a major milestone because it clears the path for a registrational trial, which is the final step needed to seek official approval to sell the drug. It also serves as a proof of concept for the business model, as this specific drug was originally identified using the company's AI models rather than traditional manual lab work.

Sources: [GlobeNewsWire](https://www.globenewswire.com/news-release/2026/11/18/3405436/0/en/recursion-announces-alignment-with-fda-on-registrational-phase-3-trial-design-for-rec-4881-in-familial-adenomatous-polyposis.html)

### Recursion Pharmaceuticals, Inc. filed an important update with the SEC

*November 3, 2026 · filing · significance: major · signal: neutral*

SEC filing on 2026-11-02: 8-K, 8-K filing: reported results; executive or director change; Regulation FD disclosure. What the filing says (its own text, every fact in the card must come from here, and NAME the specific person, role and date it gives): rxrx-20261031 0001601830 FALSE 0001601830 2025-11-04 2025-11-04 0001601830 2026-11-02 2026-11-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2026 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 41 S Rio Grande Street Salt Lake City, UT 84101 (Address of principal executive offices) (Zip code) ( 385 ) 269 - 0203 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02. Results of Operations and Financial Condition. On November 2, 2026, Recursion Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 31, 2026, the Board of Directors (the "Board") of the Company, upon the recommendation from its Nominating and Corporate Governance Committee (the "Nominating Committee"), increased the number of members of the Board from 9 to 10 and appointed Fred Hassan as Chair of the Board, effective immediately. The Board appointed Mr. Hassan as a Class II Director of the Board, with his initial term to extend until the 2029 Annual Meeting of Stockholders. Mr. Hassan has not yet been appointed to any committee of the Board. As a non-employee director, Mr. Hassan will receive cash and equity compensation paid by the Company pursuant to the Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy (the "Director Compensation Policy"), which is described under the caption "Director Compensation, 2026 Changes to the Outside Director Compensation Policy" in the Company's definitive proxy statement on Schedule 14A filed with the SEC on April 30, 2026, as amended by the Board from time to time, and Mr. Hassan will enter into an indemnification agreement with the Company on the Company's standard form of indemnification agreement for officers and directors. There are no transactions in which Mr. Hassan has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K and there are no arrangements or understandings between Mr. Hassan and any other person pursuant to which he was selected as a director of the Company. Item 7.01. Regulation FD Disclosure. On November 2, 2026, the Company released a press release announcing the appointment of Mr. Hassan as Chair of the Board, as described in Item 5.02, above. A copy of the press release is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Also on November 2, 2026, the Company released a press release announcing the data presented at CGA-IGC conference on November 2, 2026. A copy of the press release is attached hereto as Exhibit 99.3 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Also on November 2, 2026, the Company released a presentation made in connection with its earnings call on November 3, 2026. A copy of the presentation is attached hereto as Exhibit 99.4 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information furnished pursuant to Item 2.02 (including Exhibit 99.1) and 7.01 (including Exhibits 99.2 and 99.3) on this Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward Looking Statements The Company cautions you that statements contained in this report include or are based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including all statements that are not historical facts. Forward-looking statements may or may not include identifying words such as "plan," "will," "expect," "anticipate," "intend," "believe," "potential," "continue," and similar terms. These statements are subject

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000144/0001601830-26-000144-index.htm)

### We updated our thesis on Recursion Pharmaceuticals

*November 3, 2026 · news · significance: notable · signal: watch*

After Recursion Pharmaceuticals reported its November results, we updated our fair value. We moved our rating to Watch from Buy. We have added the potential for the company's new molecular glue treatment and the impact of the new chairman to our analysis. We also extended our forecast for how long the current cash balance will last into 2029.

### Recursion reports strong drug trial data and more revenue than expected

*November 2, 2026 · earnings · significance: major · signal: positive*

Recursion brought in about 20 million dollars in revenue this quarter, which was double what analysts expected. The company lost 22 cents per share, roughly in line with estimates. Because Recursion is still in the early stages of building its business, these quarterly financial swings matter less than the progress of its drug pipeline and its cash reserves. On that front, the news was encouraging. New data for REC-4881, a drug for a rare condition that causes polyps to grow in the digestive tract, showed that nearly half of patients saw their polyp burden drop by 65 percent or more. These results are a critical win for the company's central idea: that its AI platform can find effective medicines more reliably than traditional methods. The company also extended its cash runway, giving it more time to reach its goals without needing to raise more money immediately.

Sources: Company earnings report

### Fred Hassan appointed as Chair of the Board

*November 2, 2026 · news · significance: notable · signal: positive*

Recursion has named Fred Hassan as its new Chair. Hassan has over 40 years of experience in the drug industry and has previously led major pharmaceutical companies through the process of getting new medicines approved by regulators. This is a helpful addition for a young biotechnology firm. While Recursion is an expert in using AI to find drugs, it is now entering the phase where it must prove those drugs work in human trials and navigate the complex rules for bringing them to market. Having a veteran with a track record of successful drug launches at the head of the board adds significant industry expertise to the leadership team.

Sources: [GlobeNewsWire](https://www.globenewswire.com/news-release/2026/11/02/3393720/0/en/recursion-appoints-fred-hassan-as-chair-of-the-board.html)

## Recursion Pharmaceuticals, Inc. earnings

In Q3 2026, reported on November 2, 2026, Recursion Pharmaceuticals, Inc. posted earnings of $-0.22 per share against $-0.22 expected, and revenue of $18.6 million against $14.8 million expected.

The next earnings report is expected on February 24, 2027. Analysts expect $-0.21 per share. Revenue is expected around $7.6 million.

What to watch: We are watching milestone revenue from partners like Sanofi and Roche, as these payments prove that the company's AI-designed molecules are valuable enough for larger drugmakers to keep funding.

## Recent analyst activity on RXRX

- October 19, 2026: Needham Kept rating at Buy.

## What's ahead for Recursion Pharmaceuticals, Inc.

- February 24, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/RXRX
